108 related articles for article (PubMed ID: 38768047)
1. Pharmacokinetics of Generic Pediatric Dolutegravir Dispersible Tablet in Thai Young Children Living With HIV Weighing Below Twenty Kilograms.
Rungsapphaiboon A; Wacharachaisurapol N; Anugulruengkitt S; Sirikutt P; Phasomsap C; Tawan M; Saisaengjan C; Na Nakorn Y; Paiboon N; Songtaweesin WN; Tawon Y; Cressey TR; Puthanakit T;
Pediatr Infect Dis J; 2024 May; ():. PubMed ID: 38768047
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Ruel TD; Acosta EP; Liu JP; Gray KP; George K; Montañez N; Popson S; Buchanan AM; Bartlett M; Dayton D; Anthony P; Brothers C; Vavro C; Singh R; Koech L; Vhembo T; Mmbaga BT; Pinto JA; Dobbels EFM; Archary M; Chokephaibulkit K; Ounchanum P; Deville JG; Hazra R; Townley E; Wiznia A;
Lancet HIV; 2022 May; 9(5):e332-e340. PubMed ID: 35489377
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial.
Bevers LAH; Waalewijn H; Szubert AJ; Chabala C; Bwakura-Dangarembizi M; Makumbi S; Nangiya J; Mumbiro V; Mulenga V; Musiime V; Burger DM; Gibb DM; Colbers A
Clin Infect Dis; 2023 Nov; 77(9):1312-1317. PubMed ID: 37280040
[TBL] [Abstract][Full Text] [Related]
4. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Waalewijn H; Chan MK; Bollen PDJ; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Sarfati T; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Moore CL; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2022 May; 9(5):e341-e352. PubMed ID: 35189082
[TBL] [Abstract][Full Text] [Related]
6. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
7. Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low- and High-Mineral-Content Water on the Tablet in Healthy Adults.
Buchanan AM; Holton M; Conn I; Davies M; Choukour M; Wynne BR
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):577-583. PubMed ID: 28168828
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.
Brooks KM; Kiser JJ; Ziemba L; Ward S; Rani Y; Cressey TR; Masheto GR; Cassim H; Deville JG; Ponatshego PL; Patel F; Aurpibul L; Barnabas SL; Mustich I; Coletti A; Heckman B; Krotje C; Lojacono M; Yin DE; Townley E; Moye J; Majji S; Acosta EP; Ryan K; Chandasana H; Brothers CH; Buchanan AM; Rabie H; Flynn PM;
Lancet HIV; 2023 Aug; 10(8):e506-e517. PubMed ID: 37541705
[TBL] [Abstract][Full Text] [Related]
9. Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.
Viani RM; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Steimers D; Min S; Wiznia A;
Pediatr Infect Dis J; 2015 Nov; 34(11):1207-13. PubMed ID: 26244832
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA).
Prins HAB; Zino L; Svensson EM; Verbon A; de Bree GJ; Prins JM; Reiss P; Burger DM; Rokx C; Colbers A;
Int J Antimicrob Agents; 2023 Jan; 61(1):106697. PubMed ID: 36470510
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
Bunupuradah T; Techasaensiri C; Keadpudsa S; Thammajaruk N; Srimuan A; Sahakijpicharn T; Prasitsuebsai W; Ananworanich J; Puthanakit T;
Pediatr Infect Dis J; 2014 Dec; 33(12):e316-9. PubMed ID: 24983717
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.
Greener BN; Patterson KB; Prince HM; Sykes CS; Adams JL; Dumond JB; Shaheen NJ; Madanick RD; Dellon ES; Cohen MS; Kashuba AD
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):39-44. PubMed ID: 23945251
[TBL] [Abstract][Full Text] [Related]
15. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Amuge P; Lugemwa A; Wynne B; Mujuru HA; Violari A; Kityo CM; Archary M; Variava E; White E; Turner RM; Shakeshaft C; Ali S; Nathoo KJ; Atwine L; Liberty A; Bbuye D; Kaudha E; Mngqibisa R; Mosala M; Mumbiro V; Nanduudu A; Ankunda R; Maseko L; Kekitiinwa AR; Giaquinto C; Rojo P; Gibb DM; Turkova A; Ford D;
Lancet HIV; 2022 Sep; 9(9):e638-e648. PubMed ID: 36055295
[TBL] [Abstract][Full Text] [Related]
16. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of adult dolutegravir tablets in treatment-experienced children with HIV weighing at least 20 kg.
Martyn-Dickens C; Ojewale O; Sly-Moore E; Dompreh A; Enimil A; Amissah AK; Bosomtwe D; Frimpong Appiah A; Sarfo AD; Opoku T; Asiedu P; Dong SK; Kusi-Amponsah I; Maranchick N; Peloquin CA; Antwi S; Kwara A
AIDS; 2023 Jul; 37(9):1409-1417. PubMed ID: 37070558
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Bictegravir in Older Japanese People Living with HIV-1.
Kawashima A; Trung HT; Watanabe K; Takano M; Deguchi Y; Kinoshita M; Uemura H; Yanagawa Y; Gatanaga H; Kikuchi Y; Oka S; Tsuchiya K
Microbiol Spectr; 2023 Feb; 11(2):e0507922. PubMed ID: 36809124
[TBL] [Abstract][Full Text] [Related]
19. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
[TBL] [Abstract][Full Text] [Related]
20. Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition.
Elliot ER; Wang X; Singh S; Simmons B; Vera JH; Miller RF; Fitzpatrick C; Moyle G; McClure M; Boffito M
Clin Infect Dis; 2019 Jan; 68(1):87-95. PubMed ID: 29771285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
